SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

688098 (688098) News

Follow 688098 (688098) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol 688098 Asset market Sector Markets 90 days 1 Updated Sep 20, 2026, 07:53 AM UTC Open live news feed
M Shanghai Shen Lian says UB-221 phase II trial hits primary endpoint Shanghai Shen Lian Biomedical Corp (SSE:688098) says its Phase II clinical trial of UB-221 met its primary endpoint. EQUITY | Sep 20, 2026, 07:53 AM UTC